[{"id":"a7c4f9e4-84af-4d2b-9a47-edc69ca3a38e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07476729","created_at":"2026-03-28T01:40:41.936Z","updated_at":"2026-03-28T01:40:41.936Z","phase":"Phase 3","brief_title":"International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)","source_id_and_acronym":"NCT07476729","lead_sponsor":"Charite University, Berlin, Germany","biomarkers":" CD22","pipe":" | ","alterations":" CD19 positive • CD22 positive","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 750","initiation":"Initiation: 04/01/2026","start_date":" 04/01/2026","primary_txt":" Primary completion: 03/31/2033","primary_completion_date":" 03/31/2033","study_txt":" Completion: 03/31/2033","study_completion_date":" 03/31/2033","last_update_posted":"2026-03-17"},{"id":"ac4afb38-f9f0-4fe8-a6ec-8ae6a59cd318","acronym":"A041703","url":"https://clinicaltrials.gov/study/NCT03739814","created_at":"2021-01-18T18:19:08.468Z","updated_at":"2025-02-25T12:27:03.899Z","phase":"Phase 2","brief_title":"Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03739814 - A041703","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • CD22","pipe":" | ","alterations":" CD22 positive","tags":["ABL1 • BCR • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 05/08/2019","start_date":" 05/08/2019","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2025-02-24"},{"id":"110cd83b-a31c-4b26-8b05-9ad93be67a86","acronym":"","url":"https://clinicaltrials.gov/study/NCT04530565","created_at":"2021-01-18T21:41:29.599Z","updated_at":"2025-02-25T14:07:51.985Z","phase":"Phase 3","brief_title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","source_id_and_acronym":"NCT04530565","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" ABL1 T315I","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABL1 T315I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • Iclusig (ponatinib) • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • prednisone • dexamethasone • mesna • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 348","initiation":"Initiation: 01/25/2021","start_date":" 01/25/2021","primary_txt":" Primary completion: 07/01/2028","primary_completion_date":" 07/01/2028","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-19"},{"id":"65a39e57-0fe4-43a3-8e14-9aae8f76d3a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06124157","created_at":"2023-11-09T16:12:44.229Z","updated_at":"2025-02-25T14:42:30.057Z","phase":"Phase 3","brief_title":"A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)","source_id_and_acronym":"NCT06124157","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • KIT • PDGFRA • CD19 • PDGFRB • CSF1R","pipe":" | ","alterations":" CD19 expression","tags":["ABL1 • KIT • PDGFRA • CD19 • PDGFRB • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Starasid (cytarabine ocfosfate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 680","initiation":"Initiation: 05/29/2025","start_date":" 05/29/2025","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2025-02-14"},{"id":"83a8f7d9-9fcf-4758-bab6-3b6024965562","acronym":"NCI-2018-01186","url":"https://clinicaltrials.gov/study/NCT03147612","created_at":"2022-04-24T08:58:28.491Z","updated_at":"2025-02-25T16:31:11.081Z","phase":"Phase 2","brief_title":"Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03147612 - NCI-2018-01186","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • Iclusig (ponatinib) • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • Truxima (rituximab-abbs) • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 02/08/2018","start_date":" 02/08/2018","primary_txt":" Primary completion: 02/28/2027","primary_completion_date":" 02/28/2027","study_txt":" Completion: 02/28/2027","study_completion_date":" 02/28/2027","last_update_posted":"2025-02-07"},{"id":"9bf88391-bf8e-4bd2-b27f-b745a3c4ca24","acronym":"ECOG-ACRIN E1910","url":"https://clinicaltrials.gov/study/NCT02003222","created_at":"2021-01-18T09:08:51.217Z","updated_at":"2025-02-25T16:36:18.435Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT02003222 - ECOG-ACRIN E1910","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • CDKN2A • RUNX1 • IGH • ETV6 • CD4 • TCF3 • PBX1","pipe":"","alterations":" ","tags":["ABL1 • BCR • CDKN2A • RUNX1 • IGH • ETV6 • CD4 • TCF3 • PBX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • cyclophosphamide • Blincyto (blinatumomab) • etoposide IV • methotrexate • vincristine • prednisone • daunorubicin • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • Truxima (rituximab-abbs) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 488","initiation":"Initiation: 05/19/2014","start_date":" 05/19/2014","primary_txt":" Primary completion: 06/23/2023","primary_completion_date":" 06/23/2023","study_txt":" Completion: 03/14/2025","study_completion_date":" 03/14/2025","last_update_posted":"2025-02-06"},{"id":"b88cc8bc-838d-43e3-8862-07db1c3a612f","acronym":"SWOG-S1318","url":"https://clinicaltrials.gov/study/NCT02143414","created_at":"2021-01-18T09:57:21.812Z","updated_at":"2025-02-25T16:36:22.860Z","phase":"Phase 2","brief_title":"Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT02143414 - SWOG-S1318","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • PDGFRA • FGFR • PDGFRB • CD4 • CSF1R","pipe":" | ","alterations":" ABL2 fusion","tags":["ABL1 • BCR • PDGFRA • FGFR • PDGFRB • CD4 • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABL2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Blincyto (blinatumomab) • methotrexate • vincristine • prednisone • mercaptopurine delayed release (DR6MP) • mercaptopurine • Xatmep (methotrexate oral solution)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 06/30/2015","start_date":" 06/30/2015","primary_txt":" Primary completion: 06/01/2022","primary_completion_date":" 06/01/2022","study_txt":" Completion: 10/23/2025","study_completion_date":" 10/23/2025","last_update_posted":"2025-02-06"},{"id":"d6ba98f0-0642-4147-9072-780ec6d83e99","acronym":"","url":"https://clinicaltrials.gov/study/NCT03751709","created_at":"2021-01-18T18:23:36.975Z","updated_at":"2025-02-25T16:44:29.699Z","phase":"Phase 1","brief_title":"Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL","source_id_and_acronym":"NCT03751709","lead_sponsor":"Cedars-Sinai Medical Center","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blincyto (blinatumomab)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 02/14/2020","start_date":" 02/14/2020","primary_txt":" Primary completion: 03/27/2023","primary_completion_date":" 03/27/2023","study_txt":" Completion: 11/12/2024","study_completion_date":" 11/12/2024","last_update_posted":"2025-02-05"},{"id":"b1018fa9-fe4d-453b-84e2-5cea26a0b9e5","acronym":"NCI-2016-01300","url":"https://clinicaltrials.gov/study/NCT02879695","created_at":"2021-01-18T14:08:12.480Z","updated_at":"2025-02-25T16:51:44.591Z","phase":"Phase 1","brief_title":"Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia","source_id_and_acronym":"NCT02879695 - NCI-2016-01300","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD19 • CD34 • MME","pipe":" | ","alterations":" CD19 expression","tags":["CD19 • CD34 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Blincyto (blinatumomab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 10/25/2017","start_date":" 10/25/2017","primary_txt":" Primary completion: 05/22/2023","primary_completion_date":" 05/22/2023","study_txt":" Completion: 07/18/2025","study_completion_date":" 07/18/2025","last_update_posted":"2025-02-04"},{"id":"facf7f83-63bf-49f3-a6fb-2b75c0782dba","acronym":"","url":"https://clinicaltrials.gov/study/NCT05848687","created_at":"2023-05-08T15:04:02.177Z","updated_at":"2025-02-25T17:26:10.730Z","phase":"Phase 1/2","brief_title":"TINI 2: Total Therapy for Infants with Acute Lymphoblastic Leukemia II","source_id_and_acronym":"NCT05848687","lead_sponsor":"Tanja Andrea Gruber","biomarkers":" KMT2A","pipe":" | ","alterations":" CD19 positive","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • Blincyto (blinatumomab) • Zolinza (vorinostat) • dexamethasone • mitoxantrone • Komzifti (ziftomenib) • mercaptopurine"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 11/03/2023","start_date":" 11/03/2023","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2033","study_completion_date":" 12/01/2033","last_update_posted":"2025-01-31"},{"id":"50180a34-f827-4af8-ae52-29b514c2e08b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03512405","created_at":"2021-01-18T17:17:18.091Z","updated_at":"2025-02-25T17:36:00.408Z","phase":"Phase 1/2","brief_title":"Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03512405","lead_sponsor":"City of Hope Medical Center","biomarkers":" PD-L1","pipe":" | ","alterations":" CD19 positive","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Blincyto (blinatumomab)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 08/02/2019","start_date":" 08/02/2019","primary_txt":" Primary completion: 10/30/2025","primary_completion_date":" 10/30/2025","study_txt":" Completion: 10/30/2025","study_completion_date":" 10/30/2025","last_update_posted":"2025-01-29"},{"id":"e4540d59-4ee0-4d85-b168-8b3f90bd2231","acronym":"","url":"https://clinicaltrials.gov/study/NCT06317662","created_at":"2024-03-19T13:40:49.211Z","updated_at":"2025-02-25T17:39:56.997Z","phase":"Phase 2","brief_title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","source_id_and_acronym":"NCT06317662","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MCL1 • KMT2A • BCL2L1","pipe":" | ","alterations":" BCL2 expression","tags":["MCL1 • KMT2A • BCL2L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • prednisolone"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 171","initiation":"Initiation: 04/26/2025","start_date":" 04/26/2025","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2025-01-29"},{"id":"91bc7864-fd10-46ec-b629-e98e5ba03f9b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06773936","created_at":"2025-02-25T15:46:10.278Z","updated_at":"2025-02-25T15:46:10.278Z","phase":"Phase 2","brief_title":"Adding Asciminib to Usual Treatment for Adults with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT06773936","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Blincyto (blinatumomab) • prednisone • Scemblix (asciminib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 03/31/2025","start_date":" 03/31/2025","primary_txt":" Primary completion: 03/01/2029","primary_completion_date":" 03/01/2029","study_txt":" Completion: 05/01/2033","study_completion_date":" 05/01/2033","last_update_posted":"2025-01-14"},{"id":"d9427140-13fb-4cb7-b7fe-49c1e6486504","acronym":"","url":"https://clinicaltrials.gov/study/NCT03595917","created_at":"2022-04-24T08:59:32.242Z","updated_at":"2025-02-25T15:43:07.761Z","phase":"Phase 1","brief_title":"ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML","source_id_and_acronym":"NCT03595917","lead_sponsor":"Marlise Luskin, MD","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Blincyto (blinatumomab) • prednisone • Scemblix (asciminib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 07/24/2018","start_date":" 07/24/2018","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-12-27"},{"id":"770b6fe5-e7bb-4e08-b58f-bc15ae4f95a0","acronym":"NCI-2018-01078","url":"https://clinicaltrials.gov/study/NCT03263572","created_at":"2021-06-08T16:52:54.067Z","updated_at":"2025-02-25T14:50:41.961Z","phase":"Phase 2","brief_title":"Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03263572 - NCI-2018-01078","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Iclusig (ponatinib) • Blincyto (blinatumomab) • methotrexate • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 11/29/2017","start_date":" 11/29/2017","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-12-10"},{"id":"309336fe-c633-4941-857b-be9dfdd1dccf","acronym":"","url":"https://clinicaltrials.gov/study/NCT03114865","created_at":"2021-01-18T15:20:34.297Z","updated_at":"2024-07-02T16:35:00.894Z","phase":"Phase 1/2","brief_title":"A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance","source_id_and_acronym":"NCT03114865","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" KMT2A","pipe":" | ","alterations":" MLL rearrangement","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blincyto (blinatumomab) • dexamethasone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 09/05/2017","start_date":" 09/05/2017","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-27"},{"id":"9b677f8f-b3e7-4b6d-8718-36c028b32cda","acronym":"","url":"https://clinicaltrials.gov/study/NCT04329325","created_at":"2022-04-24T09:02:32.988Z","updated_at":"2024-07-02T16:35:00.993Z","phase":"Phase 2","brief_title":"Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT04329325","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 fusion","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Blincyto (blinatumomab) • dexamethasone • hydroxyurea"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 03/30/2020","start_date":" 03/30/2020","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-05-24"},{"id":"9870d7f2-3f5a-43b5-abfd-5950b19ba180","acronym":"GMALL-EVOLVE","url":"https://clinicaltrials.gov/study/NCT06061094","created_at":"2023-09-29T19:11:18.358Z","updated_at":"2024-07-02T16:35:05.904Z","phase":"Phase 2","brief_title":"Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT","source_id_and_acronym":"NCT06061094 - GMALL-EVOLVE","lead_sponsor":"Goethe University","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • Iclusig (ponatinib) • Blincyto (blinatumomab)"],"overall_status":"Recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 07/14/2023","start_date":" 07/14/2023","primary_txt":" Primary completion: 07/01/2029","primary_completion_date":" 07/01/2029","study_txt":" Completion: 07/01/2029","study_completion_date":" 07/01/2029","last_update_posted":"2024-05-06"},{"id":"3bb3cbaf-b275-4098-8e50-b212d3de0ff5","acronym":"cRIB","url":"https://clinicaltrials.gov/study/NCT05645718","created_at":"2022-12-09T14:57:54.671Z","updated_at":"2024-07-02T16:35:06.157Z","phase":"Phase 2","brief_title":"Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia","source_id_and_acronym":"NCT05645718 - cRIB","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD19 • CD22","pipe":" | ","alterations":" CD19 expression","tags":["CD19 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • cyclophosphamide • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • mercaptopurine • Neulasta (pegfilgrastim) • Depocyte (liposomal cytarabine)"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 07/14/2023","start_date":" 07/14/2023","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2024-05-03"},{"id":"8619bc98-1a57-45c6-ac5d-41c349363497","acronym":"AALL1821","url":"https://clinicaltrials.gov/study/NCT04546399","created_at":"2021-01-18T21:44:55.124Z","updated_at":"2024-07-02T16:35:08.952Z","phase":"Phase 2","brief_title":"A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)","source_id_and_acronym":"NCT04546399 - AALL1821","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • etoposide IV • methotrexate • vincristine • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection"],"overall_status":"Suspended","enrollment":" Enrollment 550","initiation":"Initiation: 12/04/2020","start_date":" 12/04/2020","primary_txt":" Primary completion: 06/30/2028","primary_completion_date":" 06/30/2028","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2024-04-18"},{"id":"7c4b8485-206a-4268-adbf-1fdeb567ca5c","acronym":"Interfant-21","url":"https://clinicaltrials.gov/study/NCT05327894","created_at":"2022-04-14T11:53:34.155Z","updated_at":"2024-07-02T16:35:11.206Z","phase":"Phase 3","brief_title":"Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia","source_id_and_acronym":"NCT05327894 - Interfant-21","lead_sponsor":"Princess Maxima Center for Pediatric Oncology","biomarkers":" KMT2A","pipe":" | ","alterations":" KMT2A rearrangement • MLL rearrangement","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blincyto (blinatumomab)"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 12/15/2022","start_date":" 12/15/2022","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 09/01/2030","study_completion_date":" 09/01/2030","last_update_posted":"2024-04-05"},{"id":"7f273db3-a538-41e9-bfa3-5f96ce6d0463","acronym":"Blina-CELL","url":"https://clinicaltrials.gov/study/NCT04554485","created_at":"2021-01-18T21:46:25.977Z","updated_at":"2024-07-02T16:35:11.419Z","phase":"Phase 2","brief_title":"Blinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphoblastic Leukemia (ALL)","source_id_and_acronym":"NCT04554485 - Blina-CELL","lead_sponsor":"Institute of Hematology and Blood Transfusion, Czech Republic","biomarkers":" ABL1 • BCR • CD19","pipe":" | ","alterations":" CD19 expression","tags":["ABL1 • BCR • CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blincyto (blinatumomab)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 05/09/2019","start_date":" 05/09/2019","primary_txt":" Primary completion: 02/29/2024","primary_completion_date":" 02/29/2024","study_txt":" Completion: 02/29/2024","study_completion_date":" 02/29/2024","last_update_posted":"2024-04-04"},{"id":"af727eab-9241-485b-bf4a-45011e7c1479","acronym":"","url":"https://clinicaltrials.gov/study/NCT05557110","created_at":"2022-09-27T14:04:47.943Z","updated_at":"2024-07-02T16:35:11.407Z","phase":"Phase 2","brief_title":"Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL","source_id_and_acronym":"NCT05557110","lead_sponsor":"Chen Suning","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Blincyto (blinatumomab)"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 09/08/2022","start_date":" 09/08/2022","primary_txt":" Primary completion: 01/05/2024","primary_completion_date":" 01/05/2024","study_txt":" Completion: 03/31/2024","study_completion_date":" 03/31/2024","last_update_posted":"2024-04-04"},{"id":"6a54e9ca-ab14-4985-b527-5f222345e52f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04307576","created_at":"2021-01-18T20:53:16.021Z","updated_at":"2024-07-02T16:35:14.109Z","phase":"Phase 3","brief_title":"A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia","source_id_and_acronym":"NCT04307576","lead_sponsor":"Mats Heyman","biomarkers":" MYC • BCL2 • KMT2A","pipe":" | ","alterations":" MYC rearrangement + BCL2 rearrangement • MLL rearrangement • MYC rearrangement • MYC translocation • BCL2 rearrangement","tags":["MYC • BCL2 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement + BCL2 rearrangement • MLL rearrangement • MYC rearrangement • MYC translocation • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • doxorubicin hydrochloride • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • vincristine • thioguanine"],"overall_status":"Recruiting","enrollment":" Enrollment 6430","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2032","study_completion_date":" 06/30/2032","last_update_posted":"2024-03-19"}]